Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage.
about
Profile of acotiamide in the treatment of functional dyspepsiaReview article: current treatment options and management of functional dyspepsiaManagement and pathophysiology of functional gastrointestinal disordersEfficacy and safety of acotiamide for the treatment of functional dyspepsia: systematic review and meta-analysisProkinetics for the treatment of functional dyspepsia: Bayesian network meta-analysis.Emerging drugs for the treatment of gastroparesis.A pilot study of acotiamide hydrochloride hydrate in patients with detrusor underactivity.Effects of acotiamide on esophageal motor function and gastroesophageal reflux in healthy volunteersAsian consensus report on functional dyspepsia.A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia.Review article: endpoints used in functional dyspepsia drug therapy trials.Emerging drugs for functional dyspepsia.Acotiamide (Z-338, YM443), a new drug for the treatment of functional dyspepsia.Acotiamide, a novel gastroprokinetic for the treatment of patients with functional dyspepsia: postprandial distress syndrome.Overlap of functional dyspepsia and GERD--diagnostic and treatment implications.Current management strategies and emerging treatments for functional dyspepsia.Functional dyspepsia--symptoms, definitions and validity of the Rome III criteria.Evaluation of acotiamide for the treatment of functional dyspepsia.Review article: adherence to Rome criteria in therapeutic trials in functional dyspepsia.Emerging pharmacological therapy for functional dyspepsia.Emerging treatments in neurogastroenterology: Acotiamade, a novel treatment option for functional dyspepsia.A double-blind placebo controlled study of acotiamide hydrochloride for efficacy on gastrointestinal motility of patients with functional dyspepsia.ACG and CAG Clinical Guideline: Management of Dyspepsia.Therapeutic effects of famotidine on chronic symptomatic gastritis: subgroup analysis from FUTURE study.Correlation Between Gastric Emptying and Gastric Adaptive Relaxation Influenced by Amino Acids.Postprandial Symptoms Felt at the Lower Part of the Epigastrium and a Possible Association of Pancreatic Exocrine Dysfunction with the Pathogenesis of Functional Dyspepsia.A Randomized, Double-Blind, Pilot Study of the Effect of Famotidine on Acotiamide Treatment for Functional Dyspepsia.The Ameliorating Effect of Lactobacillus gasseri OLL2716 on Functional Dyspepsia in Helicobacter pylori-Uninfected Individuals: A Randomized Controlled StudyCurrent management of functional dyspepsia: impact of Rome III subdivision.Acotiamide improves stress-induced impaired gastric accommodation.Functional dyspepsia and duodenal eosinophilia: A new model.Advances toward multifunctional cholinesterase and β-amyloid aggregation inhibitors.Management of functional dyspepsia: state of the art and emerging therapies.Ca2+ sensitization pathways accessed by cholinergic neurotransmission in the murine gastric fundus.Probing the Interaction between Acotiamide Hydrochloride and Pepsin by Multispectral Methods, Electrochemical Measurements, and Docking Studies.Improvement of meal-related symptoms and epigastric pain in patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan.Effect of acotiamide on gastric emptying in healthy adult humans.Asian consensus report on functional dyspepsiaGastroprotective and gastric motility benefits of AD-lico/Healthy Gut™ Glycyrrhiza inflata extractInsights into the evaluation and management of dyspepsia: recent developments and new guidelines
P2860
Q26751143-071CDDAC-4902-4B42-B417-4B5097B245CBQ26825651-96270AA2-A6B9-46B7-84DE-BBBB4504EB20Q26830012-F8DB35FF-369E-4D2E-9092-9316864BA5DEQ26991792-6D760E3A-4777-406E-9C5E-8D4044D87EE5Q33836928-E3B3B0EC-CB79-4E29-A9ED-14ACD1EBF353Q34412103-3960CFAE-8B27-4A74-A1EB-C2146271509BQ35605904-5BD1DACD-1BA4-4D7A-A19D-8E7206E7225FQ35771441-CAEE4E42-46AC-46C4-8169-F44CA986E336Q35885912-A2660E67-93C6-40DE-AB8D-4A936AF8A7EDQ35939253-81049F80-B650-4954-9F25-EF2DA72DC614Q37827564-FEF1CABF-F6EB-473B-B657-5FF4D00D2D4FQ37854060-5C8090A4-FBD2-41D8-ACD0-D18BEBF85684Q37854748-773B02C7-B979-4CFB-9CD8-4D06C6E40E10Q38051696-A47DC2E9-0233-4A7F-BE2F-305677FC5824Q38072281-D9B90BE7-13DD-4F6D-A79E-CFBF2B4281FCQ38079140-1D9D308D-A179-4696-A83A-BF8AE7CA3E24Q38080665-AE3C7306-71C2-45DA-ACE4-763FC042B57EQ38216446-0BAF2C3F-0FB6-4029-B0A1-EA11C7994F5CQ38233254-3EF575CE-95BC-44F9-89A0-0160339B9C3FQ38548532-698A6BA4-3CCB-4C79-AFC7-336EC814E0B7Q38686847-7F829DA9-9CA2-440D-91CE-4E6192EC4A56Q39378697-551CDB59-1F3F-43A8-9B5D-670C176F3DA2Q39385451-E115DCA1-9C4C-4268-82B2-97D951308F71Q39674010-F19D96F7-4E9E-4B1C-BC72-17F5520BC308Q40969293-E35BB123-A83A-4797-B7B3-51313C3B7C6FQ41073935-D9B41DE3-8A46-4E3D-B087-1AF5E452C1B8Q42375227-1BA2C95C-9643-4990-BB9E-E0DF0215E183Q42375228-0DB8E473-A2DD-40F1-8BC0-21D111B08754Q42406690-8578F250-54D3-4819-A366-C66B5F4C486AQ46341120-0A4EBDB3-06E7-4075-B514-D141F13B40FFQ47691689-A72DA728-61C4-471F-9DB9-C5E5C92A225AQ47780004-027E9D56-1E49-468D-991E-07F3B3E9E6B5Q47855083-CDD79D33-70D7-4B73-869A-EDBBD26A860CQ51046414-DEFD60B7-0FEB-42B2-89B2-4E780B12618FQ51413318-5901B7BD-8581-4C39-A610-E2905856F346Q51543924-5DF09846-9B91-4A02-9A44-5767A2813649Q51686155-6BBEE6AF-7092-44D1-B0C4-4889FF155F2DQ57728314-EE855170-AFDA-4AD1-BC3D-7BF9B7007810Q58257238-AF327D67-0E3B-4055-BDA4-ADDE0C4E90B6Q58409793-3C0CD5A3-D452-4DA3-9EFC-D2200650E0FF
P2860
Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Clinical trial: dose-dependent ...... g t.i.d. is an optimal dosage.
@ast
Clinical trial: dose-dependent ...... g t.i.d. is an optimal dosage.
@en
Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride
@nl
type
label
Clinical trial: dose-dependent ...... g t.i.d. is an optimal dosage.
@ast
Clinical trial: dose-dependent ...... g t.i.d. is an optimal dosage.
@en
Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride
@nl
prefLabel
Clinical trial: dose-dependent ...... g t.i.d. is an optimal dosage.
@ast
Clinical trial: dose-dependent ...... g t.i.d. is an optimal dosage.
@en
Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride
@nl
P2093
P1476
Clinical trial: dose-dependent ...... g t.i.d. is an optimal dosage.
@en
P2093
P304
P356
10.1111/J.1365-2982.2009.01449.X
P577
2010-01-05T00:00:00Z